NCT00354835 · OUTCOME

Overall Survival (OS)

Combination Chemotherapy and Radiation Therapy in Treating Patients With Newly Diagnosed Rhabdomyosarcoma · Source last updated 2023-01-31

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

Measure: NUMBER
Unit: Probability
Interval / dispersion: 95% Confidence Interval
Time frame: 4 years

What was measured

Probability of being alive after 4 years in the study.

Groups in this outcome

Vincristine, Dactinomycin, Cyclophosphamide (VAC)

Patients receive VAC chemotherapy comprising vincristine IV over 1 minute on day 1 of weeks 1-13, 16, 19-25, 28, 31-37, and 40;dactinomycin IV over 1-5 minutes on day 1 of weeks 1, 4, 13, 16, 19, 22, 25, 28, 31, 34, 37,and 40; and cyclophosphamide IV over 1 hour on day 1 of weeks 1, 4, 7, 10, 13, 16, 19, 22, 25, 28, 31, 34, 37, and 40. Patients may also undergo radiotherapy 5 days a week for 4-6 weeks beginning in week 4.

VAC Alternating With Vincristine, Irinotecan (VI)

Patients receive VAC chemotherapy alternating with VI chemotherapy comprising vincristine IV over 1 minute on day 1 of weeks 1-13,16, 17, 19, 20, 22-26, 28, 31-34, 37, 38, and 40; dactinomycin IV over 1-5 minutes on day 1 of weeks 1, 13, 22, 28, 34, and 40; cyclophosphamide IV over 1 hour on day 1 of weeks 1,10, 13, 22, 28, 34, and 40; and irinotecan hydrochloride IV over 1 hour on days 1-5 of weeks 4, 7, 16, 19, 25, 31, and 37. Patients may also undergo radiotherapy 5 days a week for 4-6 weeks beginning in week 4.

Group identifiers and denominators belong to this outcome only. They may differ in another outcome or in safety reporting.

Analysis denominator · Participants

Group	Source count
Vincristine, Dactinomycin, Cyclophosphamide (VAC)	222
VAC Alternating With Vincristine, Irinotecan (VI)	226

Reported measurements

Source class 1

Values in Probability · Interval/dispersion: 95% Confidence Interval
Group	Value	Spread	Lower	Upper	Comment
Vincristine, Dactinomycin, Cyclophosphamide (VAC)	0.7293	Not reported	0.6669	0.7917	Not reported
VAC Alternating With Vincristine, Irinotecan (VI)	0.7223	Not reported	0.6583	0.7862	Not reported

Complete source fields

classes

categories
measurements
group Id
OG000
lower Limit
0.6669
upper Limit
0.7917
value
0.7293
group Id
OG001
lower Limit
0.6583
upper Limit
0.7862
value
0.7223

denoms

counts
group Id
OG000
value
222
group Id
OG001
value
226
units
Participants

description

Probability of being alive after 4 years in the study.

dispersion Type

95% Confidence Interval

groups

description
Patients receive VAC chemotherapy comprising vincristine IV over 1 minute on day 1 of weeks 1-13, 16, 19-25, 28, 31-37, and 40;dactinomycin IV over 1-5 minutes on day 1 of weeks 1, 4, 13, 16, 19, 22, 25, 28, 31, 34, 37,and 40; and cyclophosphamide IV over 1 hour on day 1 of weeks 1, 4, 7, 10, 13, 16, 19, 22, 25, 28, 31, 34, 37, and 40. Patients may also undergo radiotherapy 5 days a week for 4-6 weeks beginning in week 4.
id
OG000
title
Vincristine, Dactinomycin, Cyclophosphamide (VAC)
description
Patients receive VAC chemotherapy alternating with VI chemotherapy comprising vincristine IV over 1 minute on day 1 of weeks 1-13,16, 17, 19, 20, 22-26, 28, 31-34, 37, 38, and 40; dactinomycin IV over 1-5 minutes on day 1 of weeks 1, 13, 22, 28, 34, and 40; cyclophosphamide IV over 1 hour on day 1 of weeks 1,10, 13, 22, 28, 34, and 40; and irinotecan hydrochloride IV over 1 hour on days 1-5 of weeks 4, 7, 16, 19, 25, 31, and 37. Patients may also undergo radiotherapy 5 days a week for 4-6 weeks beginning in week 4.
id
OG001
title
VAC Alternating With Vincristine, Irinotecan (VI)

param Type

NUMBER

reporting Status

POSTED

time Frame

4 years

title

Overall Survival (OS)

type

PRIMARY

unit Of Measure

Probability

Download exact source JSON → · Snapshot ctgov-results-191f4516d4760045304b24a0

Preserved source evidence · Not medical advice